Amylyx Pharmaceuticals, Inc. (AMLX) stock

AMLXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30

$30.29+0.43 (+1.44%)

Close on Nov 13, 2026Market cap $3.38BP/E –Yield –

Amylyx Pharmaceuticals price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Amylyx Pharmaceuticals's price to sales ratio was 1.3× on Jan 31, 2025, against 3.7× a year earlier.

Period	Period end	Value	Change (pts)
2025	Jan 31, 2025	1.3×	−0.0
2024	Dec 31, 2024	1.3×	−2.1
2023	Dec 29, 2023	3.4×	−218.3
2022	Apr 29, 2022	221.7×	–

Parsed from the XBRL in Amylyx Pharmaceuticals's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is AMLX.

Revenue growth-100.0% · median 342.1%

Advertisement
300 × 250

See a number that looks wrong?